MUSTANG BIO INC (MBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.39-4.78%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · MBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
MBIO — legal / regulatory event — Notice of Delisting of Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-04-17
Notice of Delisting of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 15, 2026, Mustang Bio, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance wi…
Why it matters: Revenue growth is key to understanding if the company can turn around its loss-making status. A positive trend may attract investor interest.
Supportive ifRevenue growth is speeding up again. This suggests a recovery is happening.
Worry ifRevenue growth is slowing down. This suggests the company is still having problems.
Why it matters: The company received a notice for not meeting the $1.00 share price rule. This could impact its ability to remain listed.
Worry ifThe company raises its share price above $1.00 for 10 days in a row.
Less concerning ifThe company does not meet requirements and gets a final delisting notice.
Why it matters: This report will show if Mustang Bio's financial situation is improving or worsening. Investors will closely watch revenue and loss figures.
Watch forThe earnings report shows a smaller loss than last quarter. This means things are getting better.
Also watch forThe earnings report shows a larger loss than last quarter. This means things are getting worse.
Why it matters: The earnings report will show if the company is improving its financial situation. Investors will look for signs of progress.
Watch forThe earnings report shows a reduction in losses compared to the previous quarter.
Also watch forThe earnings report shows bigger losses than last quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$215 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $591 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,450 loss on $10,000 · 74.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If sector revenue growth falls, it could impact Mustang Bio's performance. This would show a weakening market.
Worry ifSector revenue growth is lower than its usual level.
Less concerning ifSector revenue growth is higher than its usual level.
Why it matters: If healthcare sector revenue growth speeds up, it may benefit Mustang Bio. It could signal a better environment for biotech companies.
Supportive ifSector revenue growth speeds up to 9% or more.
Worry ifSector revenue growth slows down to below 9%.
Why it matters: The company received a notice of delisting due to low stock price. Resolving this is crucial for maintaining its listing.
Worry ifThe stock price closes above $1.00 for 10 consecutive business days.
Less concerning ifThe stock price remains below $1.00 for an extended period, leading to formal delisting.